Table 11.2.1.4 Open in new tab Trials of...

Table 11.2.1.4

Trials of combinations of endocrine therapies and targeted agents in metastatic breast cancer

Authors (reference)	N	Population	Intervention	Progression free survival (months) (ITT)			Clinical benefit rate (%)
Authors (reference)	N	Population	Intervention	Endocrine alone		Combination	Endocrine alone	Combination
Osborne et al. (33)	290	ER/PgR	tamoxifen +/− gefitinib	8.8		10.9	45.5	50.5
Valero et al. (34)	94	ER/PgR +	anastrazole +/− gefitinib	8.2		14.5	34	49
Mackey et al. (48)	208	HER2+ ER/PgR +	anastrazole +/− trastuzumab	2.4		4.8	27.9	42.7
Johnston et al. (49)	952	ER/PgR+ HER2 −	letrozole +/− lapatanib	≤6 months tam^a	3.1	8.3	32	44
Johnston et al. (49)	952	ER/PgR+ HER2 −	letrozole +/− lapatanib	≥6 months tam^b	15	14.7	64	62
	219	ER/PgR + HER2+		3		8.2	29	48
Baselga et al. (50)	92	ER/PgR+	Letrozole +/− temsirolimus	11.6		13.2	45	40
Chow et al. (51)	992	ER/PgR+	letrozole +/−temsirolius	9.2		9.2	43	40

Authors (reference)	N	Population	Intervention	Progression free survival (months) (ITT)			Clinical benefit rate (%)
Authors (reference)	N	Population	Intervention	Endocrine alone		Combination	Endocrine alone	Combination
Osborne et al. (33)	290	ER/PgR	tamoxifen +/− gefitinib	8.8		10.9	45.5	50.5
Valero et al. (34)	94	ER/PgR +	anastrazole +/− gefitinib	8.2		14.5	34	49
Mackey et al. (48)	208	HER2+ ER/PgR +	anastrazole +/− trastuzumab	2.4		4.8	27.9	42.7
Johnston et al. (49)	952	ER/PgR+ HER2 −	letrozole +/− lapatanib	≤6 months tam^a	3.1	8.3	32	44
Johnston et al. (49)	952	ER/PgR+ HER2 −	letrozole +/− lapatanib	≥6 months tam^b	15	14.7	64	62
	219	ER/PgR + HER2+		3		8.2	29	48
Baselga et al. (50)	92	ER/PgR+	Letrozole +/− temsirolimus	11.6		13.2	45	40
Chow et al. (51)	992	ER/PgR+	letrozole +/−temsirolius	9.2		9.2	43	40

Less than 6 months since prior adjuvant tamoxifen.

Greater than 6 months since prior adjuvant tamoxifen.

ER, oestrogen receptor; ITT, intention to treat, PgR, progesterone receptor.